Serum Interleukin-34 in Psoriatic arthritis patients and its correlation with disease 1 activity, and subclinical atherosclerosis.

Autor: Tabra, Samar Abdalhamed, Abu-Zaid, Mohammed Hassan, Elsharaby, Radwa Mahmoud, Maria, Dina, ElMiedany, Samah
Předmět:
Zdroj: Egyptian Rheumatology & Rehabilitation; 4/3/2023, Vol. 50 Issue 1, p1-8, 8p
Abstrakt: Background: Psoriatic arthritis (PsA) is a chronic multi-domains autoimmune inflammatory disorder. Patients with PsA have a significant prevalence of cardiovascular affection. Upregulated Interleukin-34 (IL-34) has been seen in many autoimmune disorders, and also in atherosclerotic plaques. The aim of this observational case–control study was to evaluate the serum levels of il-34 in PsA patients and correlate between its level and disease activity, and subclinical cardiovascular affection. Results: In this study, there were 70 PsA patients and 70 healthy volunteers, 43 patients were on Methotrexate, 6 on sulfasalazine, while 40 patients were on biological therapy either monotherapy or in combination with DMARDs. There were significant differences between PsA patients and controls in ESR, high sensitivity-CRP, total lipid profile, and IL-34 levels (p < 0.05) while there were no significant differences regarding Echo and ECG results. Also, we found that there was significant elevation in DAPSA score, hs-CRP, IL-34, and cIMT in the active patients when we compared them with inactive patients. IL-34 had significant positive correlations with DAPSA score, hs-CRP, and cIMT (r = 0.654, 0.579, and 0.658 respectively). Conclusion: Serum interleukin-34 is an important marker in PsA as its levels were elevated in PsA patients and were correlated with disease activity and subclinical cardiovascular affection. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: